solriamfetol
Sign in to saveAlso known as (R)-2-amino-3-phenylpropyl carbamate, SKL-N05, ARL-N05, ADX-N05, JZP-110, (2R)-2-Amino-3-phenylpropyl carbamate
Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.
Key facts
- Drug.image
- Solriamfetol.svg
- Drug.image_class
- skin-invert-image
- Drug.caption
- Molecular structure of solriamfetol
- Drug.image2
- Solriamfetol 3D.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Sunosi
- Drug.MedlinePlus
- a619040
- Drug.DailyMedID
- Solriamfetol
- Drug.routes_of_administration
- By mouth
- Drug.caption2
- 3D representation of a solriamfetol molecule
- Drug.class
- Norepinephrine–dopamine reuptake inhibitor; Wakefulness-promoting agent
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- BA14
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Schedule IV
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- ~95%
- Drug.protein_bound
- 13.3–19.4%
via Wikipedia infobox
~7 min read
Encyclopedic overview
14 sectionsContents
- Medical uses
- Available forms
- Side effects
- Misuse potential
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Chemistry
- History
- Society and culture
- Names
- Legal status
- Research
- References
Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea. It is taken by mouth.
Common side effects of solriamfetol include headache, nausea, anxiety, and trouble sleeping. It is a norepinephrine–dopamine reuptake inhibitor (NDRI) and is thought to work by increasing levels of the neurotransmitters norepinephrine and dopamine in the brain. Solriamfetol has also been found to act as a TAAR1 agonist, an action that may also be involved in its effects.
Excerpted from Wikipedia’s “solriamfetol” article, available under the CC BY-SA 4.0 licence.